相关实验视频

Updated: Jun 8, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

对用于治疗勃起功能障碍的PDE5抑制剂候选者的分子对接和动力学模拟分析

N Akdogan¹, R Rawat, T Ozden

¹Department of Urology, Faculty of Medicine, Cukurova University, Adana, Turkey. drtunahanates0101@gmail.com.

European review for medical and pharmacological sciences

|November 5, 2024

概括

博森伯金A对基化酶5 (PDE5) 的结合亲和力比西尔迪纳菲尔更高. 这种植物衍生化合物可能为勃起功能障碍治疗提供潜力.

科学领域:

计算化学是一种计算化学.
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

固酶5 (PDE5) 是调节光滑肌肉度的关键酶.
勃起功能障碍 (ED) 是一种经常使用PDE5抑制剂 (如西尔德纳菲尔) 治疗的疾病.
探索用于抑制PDE5的新型植物性化合物对于开发新的ED疗法至关重要.

研究的目的:

通过分子对接来评估五种植物性化合物与PDE5的结合亲和力.
为了比较这些化合物的抑制潜力与已知的PDE5抑制剂西尔德纳菲尔.

主要方法:

使用Autodock Vina v. 1.2.5.5.进行了分子对接研究.
对于排名最高的化合物,使用GROMACS 2022.2进行了分子动力学模拟.
对抗PDE5的化合物进行了结合亲和的评估 (PDB ID: 6L6E).

主要成果:

博森伯金A表现出最高的结合亲和力 (-8.8 kcal/mol),其次是金科利德B (-8.5 kcal/mol).
西尔德纳菲尔的结合亲和力为-8.1 kcal/mol.
博森伯金A和西尔德纳菲尔经过分子动力学模拟,以确认结合的稳定性.

结论:

与西尔德纳菲尔相比,博森伯格林A对PDE5具有更高的结合亲和力.
这些发现表明Boesenbergin A可能成为治疗勃起功能障碍的新疗法.

更多相关视频

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

The Equilibrium Binding Constant and Binding Strength

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium: